Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | EPOR | P19235 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841889 | 1.00 | HPGD (0.43) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL842052 | 0.89 | EPOR (0.41) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL842051 | 0.89 | EPOR (0.41) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL9329177 | 0.88 | HPGD (0.50) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL841619 | 0.86 | EPOR (0.45) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL841620 | 0.86 | EPOR (0.45) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL14019315 | 0.83 | EPOR (0.45) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL14044907 | 0.82 | EPOR (0.42) | HPGDALDH1A1L3MBTL1EPORACHE | |
| SCHEMBL24332207 | 0.82 | HPGD (0.49) | HPGDNPC1RAB9ACA12CA9 | |
| SCHEMBL1370385 | 0.82 | HPGD (0.49) | HPGDNPC1RAB9ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782903-B1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| EP-2782903-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8729061-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130137687-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013076063-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-30 | — | — | WO | disclosed |
| US-8431733-B2 | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives | VIROBAY, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8143448-B2 | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives | VIROBAY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090312571-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152474-A2 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009114633-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090234127-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234127-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | CTSS, CTSV, CTSE | HPGD 1661/4885NPC1 250/4885RAB9A 734/4885 |
| US-20130137687-A1 | NOVEL PYRROLIDINE DERIVATIVES | PYCR1, PRMT7, PRLHR | HPGD 953/4885NPC1 1501/4885RAB9A 990/4885 |
| US-20090312571-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | HCN3, NPEPPS, HACL2 | HPGD 933/4885NPC1 2684/4885RAB9A 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.